Strategies To Minimize Product Loss Of High Value Clinical Materials During Fill Finish

By Joe Page, Ph.D., VP of Development and Manufacturing

When you're manufacturing monoclonal antibodies, mRNA, oligonucleotides, peptides, or AAV therapies, product loss during fill finish carries a cost that compounds quickly. With treatment costs reaching up to $800,000 per patient annually for newer modalities, even marginal yield improvements translate into significant financial returns and better patient access to life-changing therapies.

The fill finish process creates multiple points where material can be lost: bioburden and sterility suitability testing, sterile filtration, line loss, and vial filling each carry their own risk. The good news is that targeted interventions at each stage can meaningfully reduce that waste without compromising quality or compliance.

Strategic use of development lots for bioburden, sterility, and endotoxin suitability testing protects your GMP material reserves. Selecting the right filter type and size based on your product's viscosity, bioburden load, and chemical properties reduces clogging and loss during sterile filtration. At the filling stage, precision-controlled pumping systems, real-time non-destructive weight checks, and low-volume fill needles work together to minimize hold-up volumes and rejected vials. For post-fill testing, non-destructive container closure integrity methods such as vacuum decay are preferred by regulators and avoid consuming additional product.

If you are working with high-value clinical materials, these are the practical, compliance-aligned approaches your process needs. Download the whitepaper now to identify where your fill finish operation may be losing material and how to address it at every stage.